Sobi’s research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases. They have world-class capabilities in protein biochemistry and biologics manufacturing development – validated by leading industry partners. Their organisation spans 24 countries, delivering therapies to patients in 67 countries across the globe.
Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum, Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.